NCT07282678尚未招募不适用
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder: Double-Blind, Controlled Randomized Multicenter Clinical Trial
Pulvinar Neuro, LLC1 个研究点 分布在 1 个国家目标入组 214 人开始时间: 2026年9月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 214
- 试验地点
- 1
- 主要终点
- Response rates (at least 50% reduction in Hamilton Depression Rating Scale (HDRS) score) at Week 3 Phase 1 Evaluation
研究概览
简要总结
The purpose of this research study is to investigate a closed-loop transcranial alternating current stimulation (tACS) device to evaluate its ability to reduce symptoms of major depressive disorder
详细描述
This study examines the efficacy of closed-loop transcranial alternating current stimulation (CL-tACS) for the treatment of major depressive disorder (MDD) in a double-blind, controlled parallel group multi-site clinical trial. 214 participants will be randomized into receiving 5 consecutive days of active or control CL-tACS (1:1 allocation) to achieve approximately 192 participants completing the primary endpoint at week 3, assuming a 10% lost to follow-up rate. Clinical assessments of depression and anxiety symptoms are performed at Screening, Baseline, Day 5, Follow-Up 1 (week 3), and Follow-Up 2 (week 5). Additional assessments of quality of life are included.
For subjects who are not considered responders at the Week 3 primary endpoint, there will be a phase 2 retreatment with active CL-tACS which will mirror the same 5-day protocol. Patients in this arm will complete additional data collection at Phase 2 baseline, Phase 2 Day 5, Phase 2 Follow-up 1 (phase 2 week 3), and phase 2 follow-up 2 (phase 2 week 5).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 22 years of age;
- •with at least moderate symptom severity (HAM-D17 ≥ 17);
- •who are currently in a depressive episode;
- •who have used at least 1 antidepressant in the current or previous episode, but have not found adequate symptom relief or who were not able to tolerate medication side effects;
- •who, for 6 weeks prior to enrollment, are either;
- •not taking antidepressant medication, or:
- •are taking a stable psychiatric medication regimen with one or more stable antidepressant medication dose(s) and agree to continue the same regimen throughout study participation
- •if currently engaged in depression-focused psychotherapy, have maintained stable frequency of therapy for at least 8 weeks prior to enrollment and agree to continue the same regimen throughout study participation;
- •are able and willing to comply with the protocol and follow up schedule and protocol, in the opinion of the investigator;
- •who understand English and are able to provide written informed consent;
- •who are currently under the care of a psychiatric clinician or a primary care physician for major depressive disorder, and who agree to promptly inform the study staff of any change of psychiatric or mental health providers during study participation;
- •who agree to allow any and all forms of communication between the investigators/study staff and their current or past (within 2 years) healthcare providers;
- •who agree to provide the names and verifiable contact information (email and mailing addresses, mobile and/or land-line phone numbers, as applicable) for at least two persons (≥ age 18) who reside within a 60-minute drive of their residence and whom the research staff are at liberty to contact, as they deem necessary, to ensure participant safety for the duration of study participation;
排除标准
- •Subjects with current / past six months use of an external stimulation device for MDD, including electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain or cranial nerve stimulation;
- •Subjects with (lifetime) history of failure to response to an adequate trial of ECT, TMS, or implanted vagus nerve stimulation;
- •Subjects who currently receive esketamine, ketamine, or psilocybin treatment
- •Subjects who are pregnant or of childbearing potential and not using adequate contraception, as determined by the investigator;
- •Subjects who are breastfeeding.
- •Subjects whose current depressive episode had onset within 6 months post-partum;
- •Presence of active skin disorder on the forehead that could be exacerbated by stimulation electrodes in the opinion of the investigator.
- •Subjects with clinical or historical features which, in the opinion of the investigator, make them an inappropriate candidate for participation in this trial;
- •Subjects whose current depressive episode has not responded to 3 or more adequate trials of FDA approved antidepressant medications;
- •Subjects with current suicidal ideation with plan or intent, or suicidal behavior or preparation in the past 3 months, as determined by CSSRS assessment or by the Investigator;
- •Subjects with a diagnosis of epilepsy or unexplained seizures;
- •Subjects with a diagnosis or clinical history suggestive of bipolar disorder, hypomania, mania, or psychosis, as determined by the Investigator and/or by the DIAMOND assessment.
- •Subjects currently participating, or intending to participate (during the next 3 months) in another study involving an investigational drug or device treatment that, in the opinion of the investigator, could impact symptoms of MDD or use of the investigational device;
- •Subjects with a history of intracranial surgery;
- •Subjects with implanted neurostimulators, nonremovable or implanted electrical devices or intracranial metal objects, with the exception of dental metal;
- •Subjects with cognitive impairment or memory disorders, which, in the opinion of the investigator, could impact their ability to comply with study requirements;
- •Subjects currently meeting diagnostic criteria for obsessive compulsive disorder determined by the Investigator and/or by the DIAMOND assessment;
- •Subjects who meet DSM-V criteria for moderate/severe alcohol use disorder or other substance use disorders (except tobacco/nicotine) within the past 6 months as confirmed by the DIAMOND interview;
- •Subjects who meet DSM-V criteria for moderate/severe cannabis use disorder (CUD) within the past 6 months as confirmed by the DIAMOND interview. Subjects with recreational or prescription use (including medical marijuana cards) not considered moderate to severe CUD will be included.
- •Subjects with a current neurological condition or disease which, in the opinion of the investigator, is likely to manifest a depressive syndrome or symptoms that would substantially confound the diagnosis or serial assessment of major depressive disorder.
研究组 & 干预措施
Active Closed-loop tACS
Experimental
Closed-loop individual alpha tACS daily for five consecutive days.
干预措施: Closed-loop tACS (Device)
Sham Closed-loop tACS
Sham Comparator
Sham closed-loop individual alpha tACS daily for five consecutive days.
干预措施: Sham Comparator (Device)
Open Label, Active Closed-loop tACS Retreatment
Experimental
An open label, second dose of Closed-loop individual alpha tACS daily for five consecutive days. Assignment to this arm occurs after participation in the closed label active or sham arms.
干预措施: Closed-loop tACS (Device)
结局指标
主要结局
Response rates (at least 50% reduction in Hamilton Depression Rating Scale (HDRS) score) at Week 3 Phase 1 Evaluation
时间窗: Timeframe: Baseline to Week 3
Response rates (at least 50% reduction in HDRS-D17 score) (0-52 score range, higher score is worse) in Active vs. Control groups.
次要结局
- Difference in change in Hamilton Depression Rating Scale (HDRS) in Active vs control groups between patients with MDD and GAD and patients with MDD and not GAD(Timeframe: Baseline to Week 3)
- Hamilton Depression Rating Scale (HDRS) Remission Rate at Day 5(Timeframe: Baseline to Day 5)
- Response rates (at least 50% reduction in Hamilton Depression Rating Scale (HDRS) score) at Day 5(Timeframe: Baseline to Day 5)
- Change in Hamilton Depression Rating Scale (HDRS) Score at Day 5(Timeframe: Baseline to Day 5)
- Difference in change in Hamilton Depression Rating Scale (HDRS) in Active vs control groups between patients with MDD and GAD and patients with MDD and not GAD at Day 5(Timeframe: Baseline to Day 5)
- Remission rates (Hamilton Depression Rating Scale (HDRS) score ≤ 7) at Week 5(Timeframe: Baseline to Week 5)
- Response rates (at least 50% reduction in Hamilton Depression Rating Scale (HDRS) score) at Week 5([Timeframe: Baseline to Week 5].)
- Change in Hamilton Depression Rating Scale (HDRS) score at Week 5(Timeframe: Baseline to Week 5)
- Difference in change in Hamilton Depression Rating Scale (HDRS) in Active vs control groups between patients with MDD and GAD and patients with MDD and not GAD at Week 5(Timeframe: Baseline to Week 5)
- The State-Trait Anxiety Inventory (STAI) Score(Timeframe: Baseline to week 3, Phase 1)
- Hamilton Depression Rating Scale (HDRS) Remission Rate(Timeframe: Baseline to Week 3, Phase 1)
- Change in mean Hamilton Depression Rating Scale (HDRS) Score(Timeframe: Baseline to Week 3)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Individualized Non-invasive Brain Stimulation for the Treatment of Major Depressive DisorderDepression - Major Depressive DisorderTranscranial Alternating Current StimulationNCT06874374Pulvinar Neuro, LLC40
已完成
不适用
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of DepressiontACSMajor Depressive DisorderDepressionNCT05772702Electromedical Products International, Inc.26
尚未招募
Unknown
Closed loop transcranial alternating current stimulation in depression (tACS-Depression)Mental Health - DepressionDepressionACTRN12623001264673Australian National University50
已完成
不适用
Transcranial Alternating Current Stimulation (tACS) as a novel treatment option: a proof of concept study in Adult Classic Galactosemiaclassic galactosemiaGALT deficiency1002742410028037NL-OMON49032Medisch Universitair Ziekenhuis Maastricht50
已完成
不适用
Transcranial Alternating Current Stimulation (tACS) as a Tool to Modulate P300 Amplitude in Attention Deficit Hyperactivity Disorder (ADHD)F90.0Disturbance of activity and attentionDRKS00010907Department of Psychology, European Medical SchoolCarl von Ossietzky Universität18